Clinical Trials Browser

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05067140 2025-03-17

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Phase 1/2 Active not recruiting

152 enrolled

Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT04249947 2025-02-17

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Phase 1 Terminated

40 enrolled

GenitourinaryHead & Neck

Carcinoma, Adenoid Cystic, Genital Neoplasms, Male, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Salivary Gland Neoplasms, Urogenital Neoplasms, Carcinoma, Acinar Cell, Carcinoma, Mucoepidermoid, Prostatic Neoplasms, Castration-Resistant

NCT01540994 2025-01-16

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

Phase NA Completed

12 enrolled 7 charts

Genitourinary

Genital Neoplasms, Male, Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

NCT06706921 2024-11-27

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Phase 4 Recruiting

15 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT02266745 2024-04-05

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Phase 2 Active not recruiting

109 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

NCT00946881 2024-02-07

Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

Phase 1/2 Completed

30 enrolled 12 charts

Genitourinary

Genital Diseases, Carcinoma, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT05150236 2023-12-15

ANZUP2001

Phase 2 Unknown

93 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT02578797 2023-11-09

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Phase 1 Completed

45 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT04880681 2023-05-01

Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle

Phase NA Unknown

60 enrolled

Genitourinary

Disease, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT02499952 2022-07-11

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Phase 2 Terminated

12 enrolled 14 charts

GenitourinaryGynecologic

Nonseminomatous germ cell tumor, Genital Neoplasms, Female, Genital Neoplasms, Male, Mediastinal Neoplasms, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Testicular Neoplasms

NCT04221828 2022-03-29

Trial of NanoPac Focal Therapy for Prostate Cancer

Phase 2 Terminated

1 enrolled 5 charts

Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT03490032 2020-11-17

PROfind

Phase 1/2 Completed

30 enrolled 30 charts

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Phase 3 Withdrawn

Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT02319239 2020-10-28

ESKO

Phase NA Completed

80 enrolled

Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT03077659 2019-08-20

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

Phase 2 Completed

16 enrolled 12 charts

Genitourinary

Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT01310894 2019-07-11

PCM301

Phase 3 Completed

413 enrolled

Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT00672009 2018-10-24

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

Phase 2 Terminated

11 enrolled

Genitourinary

Adenocarcinoma, Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Glandular and Epithelial, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT02606123 2018-03-01

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

28 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms

NCT01918605 2017-10-27

Protection of Rectum From High Radiation Doses Using a Spacer

Phase NA Terminated

5 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

NCT01316458 2017-06-01

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Phase 2 Completed

51 enrolled

Genitourinary

Abdominal Neoplasms, Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT01431391 2017-05-30

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

Phase 2 Completed

68 enrolled 11 charts

Genitourinary

Adenocarcinoma, Carcinoma, Genital Neoplasms, Male, Neoplasms, Neoplasms, Glandular and Epithelial, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT02483884 2017-03-22

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Phase 1/2 Terminated

30 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

NCT00707356 2016-04-19

Study of WST11 in Patients With Localized Prostate Cancer

Phase 2 Completed

42 enrolled

Genitourinary

Genital Diseases, Carcinoma, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT02049190 2015-06-24

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Phase 1/2 Unknown

75 enrolled

Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT00975429 2015-04-28

Study Using WST11 in Patients With Localized Prostate Cancer

Phase 2 Completed

86 enrolled

Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT00749502 2013-07-25

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

Phase 1 Completed

113 enrolled

GenitourinaryGynecologicLymphoidOther hematologic neoplasm

Adnexal Diseases, Endocrine System Diseases, Endocrine Gland Neoplasms, Genital Diseases, Female, Genital Diseases, Male, Genital Neoplasms, Female, Genital Neoplasms, Male, Gonadal Disorders, Neoplasms, Ovarian Diseases, Ovarian Neoplasms, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell

Clinical Trials

High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy

ACCEL

P300

PROter

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

ANZUP2001

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Trial of NanoPac Focal Therapy for Prostate Cancer

PROfind

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

ESKO

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

PCM301

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Protection of Rectum From High Radiation Doses Using a Spacer

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Study of WST11 in Patients With Localized Prostate Cancer

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Study Using WST11 in Patients With Localized Prostate Cancer

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)